Q2 EPS Estimate for Larimar Therapeutics Reduced by Analyst
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report) – Stock analysts at Wedbush reduced their Q2 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a report issued on Wednesday, April 30th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.47) per share for the quarter, down from their prior […]
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report) – Stock analysts at Wedbush reduced their Q2 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a report issued on Wednesday, April 30th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.47) per share for the quarter, down from their prior […]
